To learn more about the FDA draft guidance regarding clinical efficacy studies for biosimilars and interchangeability, click here.
To read more about G's discussion with Sarah Yim, MD, from the FDA from the recent 2025 GRx+Biosims conference, click here.
To read more on Yim's perspectives on biosimilar policy harmonization, click here.